Related Experiment Video
Updated: Mar 23, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Edoxaban in venous thromboembolism and stroke prevention: an appraisal
Marco Proietti1, Gregory Y H Lip2
1University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy.
Abstract:
Oral anticoagulation is the therapeutic cornerstone in preventing thromboembolic risk in both atrial fibrillation (AF) and venous thromboembolism (VTE). After decades of the sole therapeutic oral anticoagulation option being warfarin, the introduction of non-vitamin K antagonist oral anticoagulants has heralded a new era. Edoxaban is the latest addition to these available for clinical use. Edoxaban was as effective and safer than warfarin in preventing thromboembolic risk in AF patients. Similarly, edoxaban effectiveness and safety was evident when treating VTE patients to prevent recurrent VTE or VTE-related death. Therefore, edoxaban represents a valuable alternative in treating thromboembolic risk for AF and VTE patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

